Results from a Phase 3 clinical trial involving over 43,000 participants of an mRNA-based vaccine candidate called BNT162b2 show that it is 90% effective in preventing COVID-19 infections. The vaccine is a joint venture between Pfizer and BioNTech. Patients received…